טוען...
The novel mu-opioid antagonist, GSK1521498, reduces ethanol consumption in C57BL/6J mice
RATIONALE: Using the drinking-in-the-dark (DID) model, we compared the effects of a novel mu-opioid receptor antagonist, GSK1521498, with naltrexone, a licensed treatment of alcohol dependence, on ethanol consumption in mice. OBJECTIVE: We test the ability of GSK1521498 to reduce alcohol consumption...
שמור ב:
| הוצא לאור ב: | Psychopharmacology (Berl) |
|---|---|
| Main Authors: | , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Springer Berlin Heidelberg
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4537503/ https://ncbi.nlm.nih.gov/pubmed/26141191 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00213-015-3995-x |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|